you, morning. Good and our for call. and I'm Slide thank you going third again Thank you, X, everybody, on joining for results thank start listening. Steph, quarter to
franchise, weeks. year the data So Obviously, incredible to in quarter best-in-class start quarterly look, and by with January. as think is just we call coming -- conference in validate franchise CIDP in is at of about an I first the in pretty talked XXXX This stage. obviously, this and we coming It our wanted the for with a us that in the our little setting potentially bit setup XXXX. the But to a opportunity terms MG opportunity. a starts is this NPS CRM just
and we're which well. brepocitinib so a this excited the -- commercial which indication be new central of about see today this middle dermatomyositis, with brepocitinib, stage, for about registrational set launch and year of we'll if starting in in readout for as we program, in registrational a approval would continues trial excited also a talk that the to It year really
summary to year the jury to big and place for phase judgment Moderna Pfizer/BioNTech for our LNP the a third with this it's a in scheduled take year. currently and trial And also of litigation quarter second September
year this years just many planted milestones, So we at for ago the with of big important point. seeds of a lot a which
see we're so to excited those results. And
on Look, to comes all and we'll which we other think programs, talk of a which year, brepocitinib, little this pipelines later we late-stage the unveiled X biotech, last this pipeline, number one a about which FcRn but obviously, most BD, by down ultimately mosliciguat, of in anchored Slide in our more ongoing is with exciting and including also of call.
This Immunovant. to -- and sense, work year, really, cast at imminent. begun, in there's INDs of execution, the anchored to enormous CIDP some now ongoing for trials on MG amount cleared looking more are the Obviously, die number are an will is X, now right? March we've of Those the all But by beginning XXXX. a and clinical around X have data, which or has been be Slide initiate
a work happening ton at clinical So just Immunovant. of
study data DM in trial initiated later as PH-ILD. the this NIU as well brepocitinib -- mostly will the conduct read we've our NIU is to which continuing Obviously, then and study out ongoing the year
the the execution clinical work have it's we drive around So coming to data have between do, really year and that value. a that to we that
DM and and to sarcoid the that study hopefully we we NIU, exciting In we're year. XXXX, immunology a that. in -- franchise, indications coming data at then even the for When XX-plus look Immunovant, of sort for have this have, launches. we adding we with in orphan future, multi-blockbuster DM lot to hopefully concept proof brepo, have an a to by subsequent potential of subsequent anchored of And potential multi-blockbuster obviously, beyond how stacked
study, And end hope the on year, of Phase mostly next other year, respiratory disease. next II for to we then data set by our by XXXX, have, to we use PH-ILD and which in hope frontline up in by us
that what continues X by Slide to ours, strength is balance. our major all of cash be is And anchored on of a which
We and stock billion about additional the That so end bought cash of million as buybacks. in far We includes share billion authorized of of as marketable XXXX. have in $XXX $X.X securities back XX/XX. for $X
and milestones Organon, while about to and received obligations, all talked meaningful We sale of that debt upside closed a We the last million, year. royalties. in our of removed about of VTAMA Dermavant $XXX keeping of lot
continues or much be hope fruitful in months we'll very seen, And business and to ever I come. fruitful most environments adding most then this that pipeline the the that and to be development expect to among we've the
to et now talk something something So us, get It'll public a is soon, have further on. now opportunity new cetera, a for that's clinicaltrials.gov bit a called proof-of-concept I is program a which want disease sarcoidosis. new indication. to cutaneous study excited out, initiated third but turn our to going about brepocitinib, be little we're in on for a we This probably
about are indications So if second, that into Priovant our unmet dual turn at to with I'll tailored TYKX strategy JAKX Slide -- specifically developing to high this and needs is fits again it in really this well, our mechanism. you XX, talk and a
the in disfigurement. therapies, pretty diseases somewhere to between First can that disease, these patients. it's of tough It's no XX,XXX studying of cutaneous uncontrolled similar, and There's brepo. with very severe XX,XXX for patients of disease the in terms all, scope other sarcoidosis sort bluntly, are approved we and result of with
what indications JAK-treated then sarcoidosis. well suited we've about ThX we'll inhibition so not XX and JAKX There some the from And seen -- data about is different so patients, dual think we proof-of-concept the talk TYKX studying. from this is other more in of and to immunophenotype we're particularly
of concentration that little then a DM in DM NIU with price talk that. of terms to point. a bit about in base with aligned going it's we're potential orphan prescriber So overlap And terms and
us we of a go So place here. makes a to from for as it think lot sense
on XX large patients, there's reminder, looks NIU, been Slide similar the need, similar. well, the and that. very class some DM pretty patient our medical nothing biology, benefit Obviously, JAKX meaningful concept a under to last these prevalence. on approved in unmet overall yes, proof met tailored brepo, indications by There both, we're strategy and our patients. a unique got need And in think view, really in to where high mechanism, focused be It's a with well-suited any far is it As deliver liabilities years. of unmet will the with JAK ability of we XX our outweighed to
really So we're excited to add our portfolio. this to
a That study XX, proof was investigator-initiated in patients was of data. trial There open-label little bit inhibition an XX is, in of Yale, an long-standing providing at cutaneous JAK There for on concept of concept sarcoid. proof Slide with of tofacitinib CS.
achieved considering in of XX about of X of and is them talked resolution that CSAMI twice what meaningful achieved disease. And with mean, reduction months, CSAMI, was day tofa all going a for on lot XX. we milligrams [indiscernible] them patients it complete study, X And about to the -- X a patients of CS and clinically of here
studies. remarkable a But big for of data again, sick that with improvement. So pretty pretty all study, from patients, the open-label caveats
proof-of-concept a us into gives that bit of comfort going study. this So
Slide interferon inhibition X exactly type like of we and collection we cytokines. gives upregulation with a of ThX-type polarization, cytokines the important TYKX and And which -- predominant the mediating XX, that ThX more perspective. then sarcoidosis both lung dual skin obviously polarization And of physiology immunity sort on JAKX, and think from main know just us are potentially to of the is in kind of IL-XX, tissue. profile right which that the
feel gun. coming a So at this good really uniquely with we about big
strong generated skin on in has data particularly Slide Brepo inflammatory XX, disease.
have best-in-class data all that's But cross-trial comparisons the data available. among the JAK whichever a with best-in-class in psoriasis, alopecia other on plaque are cross-trial So with we seen. inhibitors in have see been can HS and you these comparison reasonable
disease into about have, where coming of an feel inflammatory of skin data pretty So well good good out we brepocitinib. we as entering area sort again
XX, as study XX data XX-week is get hope of the And and year. we yes, half XX design to X brepo in on doses, second placebo. it's slated as next brepo a testing well The study
more to So as come that study enrolling. starts
a Cool. on just now what I'm upcoming happened recently reminder to what's Slide at of of XX. going anti-FcRN our Immunovant, starting franchise to sort and move in on
batoclimab out much we starting and help indications. different CIDP We've year, collectively, going worth this you X know, data this for another think studies which that as that in and many X this can obviously will we confidence, we MG a across which suppression get better data reduction trials do our different clinical anti-FcRn by IgG these patients across confidence results how seen have, of hope show antibodies in out metrics. coming we IgG clinical indications So deeper better that patients including we're with to bit quite across your bolster deeper different But of outcomes. now with XXX all of can us quarter,
has So nobody as or we're data. a looking Roivant of just Immunovant at forward to reminder, by seen which, generating that the data, any way, this
of last my voice any different should X be the my tone from months. of voice of in So tone interpretation no
first suited sort is followed The that well just trial therapy first we version look in data or at. what treatment on of these MG, is us, this an and understanding hopefully, clear we upcoming chronic low well picture possibility give with high with period patients is doses, The that design. phase with of study that the period, so that. potential maintenance rerandomization every to week treating XX-week response X think induction of patients a dose the by these of either of from a in into this a will Rescue think like of XX-week and Slide And they're where dose It XX, as a a trial reminder as the low, on. other of
about good So feeling design. trial the
shown bato of readout design from period We also CIDP our Page have Phase XX. IIb the That study. X upcoming is on
point. all and dose forward highlighted these the piece we're which in very well period designs at as possibility this you're that to possible XX-week randomized after X, period. designs. here, treatment questions red the be are is response They pretty some in think rates to response able looking But to answer familiar I complicated about with the
Slide XXXX best-in-class XX of other in to don't view, a our we attributes see programs. continues, that Look, have combination potentially on in
IgG deep subcu We injection. we're a or I milligrams XXX going have suppression data IgG by our simple delivered thereabouts of lowering, be XX% to dosing about suggests with continue continued to reach able Phase to
albumin XXXX impact I data, to does or not, appear Phase in LDLs. our
there. minimal no So effect
have We convenient administration.
in again a We by a up second. user-friendly auto-injector have will proven And not we market we're that as launching be XXXX, IP with. to including highlight a that extensions. delivered We'll reminder,
a So we drug in really long be with think could the that runway class. best
ml XX of injection all HCP like device. sort seconds we picture is also are injector from It Slide be We the It the administration. as successful at-home It's well-proven looks widely XX, to pivotal will our subcu only a X pivotal our a our On this ever of thank a benefit. It's starting a administration. less trials And Needless think standard starting real injectors, trials will think a than this true of auto-injector. -- the with reminder, we and pretty be volume. a technology. developed is we other FcRn in auto inception. leverages say, as a it
So to factor. looking form to forward that continuing progress
to And in XXXX XX, Slide then into is that the long event run getting the here matter. me really main look, on indications
we high have tremendously in II we where an shows that with that for about autoantibody a disease response with we where are rate extremely us excited success. run potential -- first-in-class We a we best-in-class and we own levels response that sets Phase think have high up lower and dose unmet indication that well our good need, study Graves' have
we are from an you're more at disease and positioned to about years with the hearing come, a We going think, agent lot is excited be pack maximally that Graves' that to Immunovant in and be think world, to benefit the front deliver patients. of to and the to from we those both months
then last that talked that Immunovant, running And study also late We in announced, treat to arthritis. we're a we've rheumatoid year. about at difficult
have for the for up excited We on for it lot a much of that do you are into who of We once options answer how can patients get us quick RA trial. we sets landscape. a think that these not corner other
soon. in news but We've a clear I'm so them. X lot to said, near of those this indications, and X we that approved, nonetheless, we'll in coming touch sure the on about As IND CIDP, forward are in MG Obviously, Immunovant, of there leaves collectively X the and be term also near but is and looking we're about INDs future. talking talked only unannounced,
Finally, in milestones terms bit on Genevant upcoming these XXXX, little in litigation. time LNP we've over calls of talked major only about a the
are this calendar. obviously, the decision year, Pfizer-BioNTech be hearing We of not in on -- from half hoping any could Markman first upcoming, the for the fixed so that market
it So theory, could, in anytime. come
jury of And then in summary progress, features the will that of in trial, quarter the where Moderna September of quarter, judgment this the year. trial have half how the we will important scheduled trial learn we by second phase this third second in court year, for -- from the followed important will
a the the significant at of Moderna least a learn year piece -- puzzle will where here. really to So answer we
out to forward looking So well. that as playing
up with financial Slide Q&A. wrap and a update open on then up quickly I'll So to XX
a approval external no January with the in Roivant's straightforward on $X.X million of from of of billion million R&D of End alongside quarter dermatitis excludes or atopic given which placement the of And January debt well of $XXX $XX cash, $XXX G&A which relatively balance the close there. million. we So milestone adjusted raised of as was from million as expense $XX transaction. the the sheet from $XXX said, perspective, financial the million or the as Organon following investment quarter, private million. $XXX capital
finance the on that side. about that's so And
beyond. And bunch to we've on XX, we Slide which we catalyst continue excited feel the sort near have some important with we exciting pipeline really on with some hopefully have in about quite of which year, again, adding be record. some for a rich of calendar year a like future of about to coming, milestones, Look, talked this our stacking things the our of
back end prepared over for for and remarks Q&A. So it turn my with again Thank operator that, the you will I listening. to
